By Robert Jamerson
Zacks upgraded shares of MiMedx Group (NASDAQ:MDXG) from a hold rating to a strong-buy rating in a report issued on Friday. They currently have $11.00 target price
on the stock.
Zacks’ analyst wrote, “MiMedx Group, Inc. (MiMedx Group) is a development stage company that integrates, develops and manufactures patent protected biomaterial-based products for the Orthopedics and Spine market categories. The Company’s two proprietary biomaterials are collafix and hydrofix, which are applied in the treatment of traumatized tissue and structures. The collafix products are assembled from a strong, collagen-fiber based technology that can be used to augment the repair of soft-tissue and connective tissue injuries. The hydrofix products are constructed of durable hydrogel, a water-based biomaterial, that find their use in spinal and orthopedic applications, Its products include Hydrofix Vaso Shield, indicated as a cover for vessels following anterior vertebral surgery; and Hydrofix Spine Shield, an adhesion barrier for use as a spine cover after vertebral surgery. MiMedx Group, Inc. is headquartered in Marietta, Georgia. “ 
Zacks has also modified their ratings on a number of other stocks in the few days. The firm reiterated its buy rating on shares of Dynegy Inc.. They have a $37.00 price target on that stock. Also, Zacks downgraded shares of Cheniere Energy Partners LP from a strong-buy rating to a buy rating. Their analysts now have a $34.00 price target on that stock. Finally, Zacks upgraded shares of Bank of Nova Scotia from a sell rating to a hold rating.